Insmed Incorporated (INSM) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen.
Is Insmed Incorporated stock overvalued or undervalued in 2026?
As of October 29, 2026, Insmed Incorporated (INSM) trades at $111.59 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Insmed Incorporated
Market cap $24B · 52 weeks $92 – $211 (47 % below the high) · P/E no earnings · 2027 expected P/E 137× · Dividend none · Next earnings February 18, 2027 · expected EPS $-0.29 · Closing price, Oct 29 · accounts published Oct 29.
- Valuation: P/Sales 29.0× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 2 of 8 (disappointing).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 1 of 4 pass
- Cash Runway 18 meses, fails.
- R&D / Market cap 3.2 %, fails.
- Market cap / Cash 16.7×, fails.
- Total Debt 0.6×, passes.
- Annual cash burn $4.38, info.
Against its peers (reference peers) — Insmed Incorporated: P/E —; EV/EBITDA —; ROIC -48.9 %; $24.4B. United Therapeutics Corporation (P/E 20.9×; EV/EBITDA 14.1×; ROIC 17.7 %; $25.0B), Liquidia Corporation (P/E 30.4×; EV/EBITDA 21.8×; ROIC 46.9 %; $3.7B), Genmab A/S (P/E 31.3×; EV/EBITDA 27.7×; ROIC 9.9 %; $24.4B).
Profitability
| Return on Equity | -111.26% |
| Return on Invested Capital | -48.85% |
| Return on Assets | -41.63% |
| Gross Margin | 83.27% |
| Operating Margin | -71.86% |
| Net Margin | -76.94% |
Financial Health
| Debt / Equity | 0.77 |
| Current Ratio | 3.72 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 10.39 |
Price Performance
| 1 month | -2.23% |
| 3 months | +13.17% |
| Year-to-date | -35.88% |
| 1 year | -42.54% |
| 3 years | +345.29% |
| 5 years | +270.12% |
| 10 years | +765.04% |
Related companies: UTHR · LQDA · VRTX · 0QZU.L · MRNA · 0R2M.L · REGN · ARGX
Explore sector: Healthcare · Biotechnology
More sections of INSM: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks